Characterization of Signs and Symptoms of Participants With and Without Meibomian Gland Dysfunction
Completed
- Conditions
- Meibomian Glands
- Interventions
- Procedure: Meibum Expression
- First Posted Date
- 2013-11-08
- Last Posted Date
- 2014-08-15
- Lead Sponsor
- Allergan
- Target Recruit Count
- 75
- Registration Number
- NCT01979887
Safety and Efficacy of Bimatoprost/Timolol (Ganfort®) Ophthalmic Solution in Korea
Completed
- Conditions
- Glaucoma, Open-AngleOcular Hypertension
- Interventions
- Drug: bimatoprost/timolol
- First Posted Date
- 2013-11-06
- Last Posted Date
- 2015-09-28
- Lead Sponsor
- Allergan
- Target Recruit Count
- 756
- Registration Number
- NCT01976624
Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat Chronic Migraine in Korea
Completed
- Conditions
- Migraine DisordersHeadache
- Interventions
- Biological: botulinum toxin Type A
- First Posted Date
- 2013-11-06
- Last Posted Date
- 2015-04-08
- Lead Sponsor
- Allergan
- Target Recruit Count
- 402
- Registration Number
- NCT01976611
A Safety and Effectiveness Study of JUVÉDERM VOLIFT® XC Versus Control for Moderate to Severe Nasolabial Folds
Not Applicable
Completed
- Conditions
- Moderate to Severe Nasolabial Folds
- Interventions
- Device: JUVEDERM VOLIFT® XCDevice: Control
- First Posted Date
- 2013-11-06
- Last Posted Date
- 2019-05-10
- Lead Sponsor
- Allergan
- Target Recruit Count
- 126
- Registration Number
- NCT01976663
- Locations
- 🇺🇸
Total Skin and Beauty Dermatology Center P.C., Birmingham, Alabama, United States
🇺🇸Vitiligo and Pigmentation Institute of Southern California, Los Angeles, California, United States
🇺🇸Skin Research Institute, Coral Gables, Florida, United States
Safety and Efficacy of Dexamethasone (OZURDEX®) Intravitreal Implant in Korea
Completed
- Conditions
- Retinal Vein Occlusion
- Interventions
- First Posted Date
- 2013-11-06
- Last Posted Date
- 2016-01-13
- Lead Sponsor
- Allergan
- Target Recruit Count
- 724
- Registration Number
- NCT01976650
JUVEDERM® Ultra XC vs. Belotero Balance® for Perioral Lines
Not Applicable
Completed
- Conditions
- Patients With Moderate to Severe Perioral Lines
- Interventions
- Device: JUVEDERM® Ultra XCDevice: Belotero Balance®
- First Posted Date
- 2013-10-28
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Allergan
- Target Recruit Count
- 138
- Registration Number
- NCT01970397
Tear Collection in Adult Volunteers
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Procedure: Tear Sample Collection
- First Posted Date
- 2013-10-25
- Last Posted Date
- 2014-11-21
- Lead Sponsor
- Allergan
- Target Recruit Count
- 35
- Registration Number
- NCT01969162
A Retrospective Chart Review to Evaluate Diagnosis and Treatment of Chronic Migraine and Headache
Completed
- Conditions
- HeadacheMigraine Disorders
- Interventions
- Other: No Intervention
- First Posted Date
- 2013-09-19
- Last Posted Date
- 2016-03-15
- Lead Sponsor
- Allergan
- Target Recruit Count
- 459
- Registration Number
- NCT01946126
OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder
Phase 4
Completed
- Conditions
- Overactive Bladder
- Interventions
- Biological: onabotulinumtoxinADrug: Normal saline
- First Posted Date
- 2013-09-18
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- Allergan
- Target Recruit Count
- 254
- Registration Number
- NCT01945489
- Locations
- 🇺🇸
Genesis Research LLC, San Diego, California, United States
🇺🇸Deaconess Clinic, Inc., Newburgh, Indiana, United States
🇺🇸Urology Associates of Norwalk, Norwalk, Connecticut, United States
Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns
Phase 4
Completed
- Conditions
- Urinary Bladder DiseasesMultiple Sclerosis
- Interventions
- Behavioral: Systematic Screening and Education Regimen
- First Posted Date
- 2013-08-29
- Last Posted Date
- 2016-05-27
- Lead Sponsor
- Allergan
- Target Recruit Count
- 120
- Registration Number
- NCT01930799
© Copyright 2025. All Rights Reserved by MedPath